CDK4 and breast cancer: These findings suggest that OTX015 synergizes with abemaciclib in the treatment of ESR1 mutant, endocrine therapy–resistant breast cancer, both in vitro and in vivo, and is superior to the current standard of care treatment of combination of CDK4/6 inhibitor with fulvestrant.